Kaisa Health Group Holdings Limited (Kaisa Health) reported that its wholly owned subsidiary, Qinghai Pharmaceutical Co., Ltd., received a Drug Registration Certificate from China’s National Medical Products Administration (NMPA) on 21 July 2026 for Hydromorphone Hydrochloride Injection with a specification of 1 ml: 2 mg.\n\nThe injectable opioid is indicated for moderate-to-severe cancer pain, acute postoperative pain and intensive-care analgesia—areas characterised by persistent, inelastic demand. Hydromorphone Hydrochloride Injection is classified as a narcotic drug and is listed in the “Catalogue of Narcotic Drugs for Medical Use (2025 Edition).”\n\nRegulations issued under NMPA Announcement 2025-No. 51 limit the number of approved domestic manufacturers of this category of narcotic drugs to three, creating a highly concentrated competitive environment. With the new registration, Qinghai Pharmaceutical becomes one of only three companies nationwide authorised to produce Hydromorphone Hydrochloride Injection.\n\nManagement highlighted that the approval strengthens Kaisa Health’s portfolio of high-barrier narcotic analgesics and is expected to underpin sustained revenue growth by leveraging the product’s status as a standard potent analgesic for Grade II and above hospitals across China.